Frontpage Hero

Because we care, we need to act

Sobi 2018 Annual and Sustainability Report

Sobi 2018 Annual and Sustainability Report

"2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see this as an important stepping stone. In the Annual and Sustainability Report, we outline how the strong growth we delivered throughout 2018 is fuelling our vision of becoming global leaders in providing innovative treatments that transform life for people with rare diseases".

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has commenced a tender offer through its indirect wholly owned subsidiary Dragonfly Acquisition Corp. (Dragonfly) to purchase all outstanding shares of Dova Pharmaceuticals, Inc. (Dova)...

10/11/2019 - 14:00

The study, conducted among 51 people living with haemophilia and 18 healthcare professionals found that there is still an unmet need for more flexible and personalised approaches to treatment to allow PwH to lead lives beyond the bleeding disorder.

“The research shows...

10/04/2019 - 15:00

As per 30 September 2019, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 299,977,839 shares. All shares are common shares. The total number of votes is 299,977,839. The increase in the number of shares and votes results from an issue...

09/30/2019 - 08:30

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non...

09/30/2019 - 08:00
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden